Zhu Yan-Juan, Zhang Hai-Bo, Liu Yi-Hong, Zhu Ya-Zhen, Chen Jun, Li Yong, Bai Jian-Ping, Liu Li-Rong, Qu Yan-Chun, Qu Xin, Chen Xian, Zheng Guang-Juan
Department of Oncology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China.
Department of Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong 510120, P.R. China.
Oncol Lett. 2017 Aug;14(2):2573-2579. doi: 10.3892/ol.2017.6425. Epub 2017 Jun 20.
The present study aimed to determine the diagnostic concordance of plasma epidermal growth factor receptor (EGFR) mutation using droplet digital polymerase chain reaction (ddPCR) with tumor tissue samples and the predictive clinical significance of plasma EGFR mutation concentration. Plasma DNA samples from patients with non-small cell lung cancer (NSCLC) were analyzed for EGFR exon 21 codon 858 (L858R) mutation, deletion of exon 19 (ex19del) and exon 20 codon 790 (T790M) mutation using ddPCR. Firstly, the mutations in the plasma samples were compared with the matched tumor samples to determine the concordance. Secondly, image examination follow-ups were analyzed to assess the association between plasma EGFR mutation concentration and patients' response to EGFR-tyrosine kinase inhibitors (TKIs). A total of 51 patients with NSCLC were enrolled, including 48 newly diagnosed patients. Compared with tumor tissue samples, the sensitivity and specificity of ddPCR were 76.19% (16/21) and 96.55% (28/29) for mutant L858R, and 88.89% (8/9) and 100% (41/41) for ex19del, respectively. No patient exhibited the T790M mutation in the tumor tissue or plasma samples. Furthermore, 5 patients with the L858R mutation and 4 patients with ex19del in plasma and tumor tissue samples had been followed up with image examination for ≥3 months following EGFR-TKI treatment. The baseline mutant EGFR concentrations were positively correlated with a reduction in tumor burden (Spearman's r=0.7000, P=0.0358). When analyzed separately, ex19del concentrations (Spearman's r=1.0000, P<0.0001) were also positively correlated with the reduction, while mutant L858R concentrations were not (Spearman's r=0.7000, P=0.1881). In the present study, detection of plasma EGFR mutations using ddPCR exhibited sufficient concordance with tumor tissue sample results. Baseline plasma mutant EGFR and ex19del concentrations were significantly and positively correlated with response to EGFR-TKIs.
本研究旨在确定使用液滴数字聚合酶链反应(ddPCR)检测血浆表皮生长因子受体(EGFR)突变与肿瘤组织样本的诊断一致性,以及血浆EGFR突变浓度的临床预测意义。采用ddPCR分析非小细胞肺癌(NSCLC)患者的血浆DNA样本,检测EGFR第21外显子858密码子(L858R)突变、第19外显子缺失(ex19del)和第20外显子790密码子(T790M)突变。首先,将血浆样本中的突变与匹配的肿瘤样本进行比较,以确定一致性。其次,分析影像学检查随访结果,评估血浆EGFR突变浓度与患者对EGFR酪氨酸激酶抑制剂(TKIs)反应之间的关联。共纳入51例NSCLC患者,其中48例为新诊断患者。与肿瘤组织样本相比,ddPCR检测L858R突变的敏感性和特异性分别为76.19%(16/21)和96.55%(28/29),检测ex19del的敏感性和特异性分别为8,89%(8/9)和100%(41/41)。肿瘤组织或血浆样本中均未发现T790M突变患者。此外,5例血浆和肿瘤组织样本中存在L858R突变的患者以及4例存在ex19del突变的患者在接受EGFR-TKI治疗后接受了≥3个月的影像学检查随访。基线突变型EGFR浓度与肿瘤负荷减轻呈正相关(Spearman秩相关系数r=,7000,P=,0358)。单独分析时,ex19del浓度(Spearman秩相关系数r=1.0000,P<,0001)也与肿瘤负荷减轻呈正相关,而L858R突变浓度则不然(Spearman秩相关系数r=,7000,P=,1881)。在本研究中,使用ddPCR检测血浆EGFR突变与肿瘤组织样本结果具有足够的一致性。基线血浆突变型EGFR和ex19del浓度与EGFR-TKIs反应显著正相关。